Journal
JOURNAL OF PHARMACY AND PHARMACOLOGY
Volume 69, Issue 4, Pages 463-470Publisher
OXFORD UNIV PRESS
DOI: 10.1111/jphp.12666
Keywords
bioequivalence; lamivudine; zidovudine; nevirapine; paediatric; tablet; two-way crossover; study
Categories
Funding
- Roosevelt University
- Elim Pediatric Pharmaceuticals
- Duquesne University
- National Institute of Health (NIH) [1 R03 HD059540-01]
Ask authors/readers for more resources
Objective The bioequivalence study was conducted to compare the developed paediatric fixed-dose combination (FDC) zidovudine/lamivudine/nevirapine (60/30/50 mg) tablet - the test formulation - with the combined mixture of single-entity innovator products (reference product). Methods A single-dose open-label randomized two-way crossover study was conducted in healthy adult African volunteers after an informed consent was obtained. The 24 volunteers, divided into two groups, were administered the products after an overnight fast on two treatment days with 14 days of washout period. Blood samples were collected for 96 h and analysed using a validated RPHPLC-UV assay method. Pharmacokinetic (PK) parameters (non-compartmental model) were assessed with WinNonlin (R) software. Analysis of variance (ANOVA) and FDA bioequivalence statistical criterion of 90% CI or 80% to 125% range (set at P < 0.05) of least square geometric means (LSGM) ratios of test: reference product for C-max, AUC(0-t), and AUC(0-infinity) were determined. Results ANOVA indicated that the period, sequence and formulation had no significant effect on the PK parameters (P > 0.05). The 90% CIs for all the drugs were within the 80% to 125% range. Conclusion The developed FDC tablet is bioequivalent to the reference product.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available